Melatonin Improves DNA Damage Repair Capacity in Night Shift Workers
By Elana Gotkine HealthDay Reporter
TUESDAY, Feb. 25, 2025 -- For night shift workers, melatonin supplementation seems to improve oxidative DNA damage repair capacity, according to a study published online Feb. 24 in Occupational & Environmental Medicine.
Umaimah Zanif, from the British Columbia Cancer Research Institute in Vancouver, Canada, and colleagues examined whether melatonin supplementation would improve oxidative DNA damage repair among night shift workers in a parallel-arm randomized placebo-controlled trial involving 40 night shift workers. Supplements were consumed before day sleep during a four-week period. Creatinine-adjusted 8-hydroxy-2'-deoxyguanosine (8-OH-dG) measured in urine was an indicator of oxidative DNA damage repair capacity, with higher concentrations indicative of better repair.
The researchers observed a borderline statistically significant 1.8-fold increase in urinary 8-OH-dG excretion during day sleep in association with the melatonin intervention (95 percent confidence interval, 1.0 to 3.2; P = 0.06). During the subsequent night shift, there was no statistically significant difference in 8-OH-dG excretion (melatonin versus placebo excretion ratio, 0.9; 95 percent confidence interval, 0.6 to 1.5; P = 0.7).
"Assessing long-term efficacy is critical since those who work night shifts for many years would need to consistently consume melatonin supplements over that time frame to maximize the potential cancer prevention benefits," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-02-26 06:00
Read more

- Otsuka Files Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy
- Girl Scouts Say Cookies Are Safe Despite Lawsuit Claiming They Contain Heavy Metals
- Disruptions in Amino Acid, Lipid Metabolism May Signal Tardive Dyskinesia
- AI Improves Diagnosis Of Celiac Disease
- New Bill Targets Harmful Ingredients in California School Food
- FDA Approves TNKase for Acute Ischemic Stroke
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions